
You must be at least 21 years old to access this website.
Our Products are for research and/or investigative purposes and are not suitable for direct human consumption or consumers, nor are they intended for clinical or therapeutic use. The statements and products listed on this website are not intended to diagnose, treat, cure, or prevent any disease. As such, they have not been evaluated or approved by the Federal Food and Drug Administration (the “FDA”). We are not a compounding pharmacy or outsourcing facility as defined under either Section 503A and 503B of the Federal Food, Drug, and Cosmetic Act.
Your cart is empty
Add compounds to get started
Research Comparison
PT-141 (bremelanotide) and MT-2 (melanotan II) are both melanocortin-receptor agonists, but with different selectivity. PT-141 is studied mainly for central MC3R/MC4R signaling, while MT-2 is an α-MSH analog studied across melanocortin receptors including MC1R.
| Attribute | PT-141 | MT-2 |
|---|---|---|
| Receptor focus | MC3R / MC4R | MC1R and broader melanocortin |
| Derivation | Bremelanotide (MT-2 metabolite) | α-MSH analog |
| Research focus | Central neuroendocrine signaling | Melanocortin receptor pharmacology |
Yes — PT-141 (bremelanotide) is a metabolite of MT-2 (melanotan II). Both are melanocortin-receptor agonists, but PT-141 is studied more selectively for MC3R/MC4R signaling.